These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 9398846)
21. Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells. Rosenthal EL; Johnson TM; Allen ED; Apel IJ; Punturieri A; Weiss SJ Cancer Res; 1998 Nov; 58(22):5221-30. PubMed ID: 9823336 [TBL] [Abstract][Full Text] [Related]
22. Reduced transplant arteriosclerosis in plasminogen-deficient mice. Moons L; Shi C; Ploplis V; Plow E; Haber E; Collen D; Carmeliet P J Clin Invest; 1998 Nov; 102(10):1788-97. PubMed ID: 9819364 [TBL] [Abstract][Full Text] [Related]
23. Plasminogen activators in abdominal aortic aneurysmal disease. Reilly JM Ann N Y Acad Sci; 1996 Nov; 800():151-6. PubMed ID: 8958990 [TBL] [Abstract][Full Text] [Related]
24. Prevention of aneurysm development and rupture by local overexpression of plasminogen activator inhibitor-1. Allaire E; Hasenstab D; Kenagy RD; Starcher B; Clowes MM; Clowes AW Circulation; 1998 Jul; 98(3):249-55. PubMed ID: 9697825 [TBL] [Abstract][Full Text] [Related]
25. Matrix metalloproteinases. Their role in degenerative chronic diseases of abdominal aorta. Palombo D; Maione M; Cifiello BI; Udini M; Maggio D; Lupo M J Cardiovasc Surg (Torino); 1999 Apr; 40(2):257-60. PubMed ID: 10350113 [TBL] [Abstract][Full Text] [Related]
26. The effect of tissue type-plasminogen activator deletion and associated fibrin(ogen) deposition on macrophage localization in peritoneal inflammation. Cook AD; Vlahos R; Massa CM; Braine EL; Lenzo JC; Turner AL; Way KJ; Hamilton JA Thromb Haemost; 2006 Apr; 95(4):659-67. PubMed ID: 16601837 [TBL] [Abstract][Full Text] [Related]
27. Genetic deletion of tissue-type plasminogen activator (t-PA) in APOE3-Leiden mice reduces progression of cholesterol-induced atherosclerosis. Rezaee F; Gijbels M; Offerman E; Verheijen J Thromb Haemost; 2003 Oct; 90(4):710-6. PubMed ID: 14515193 [TBL] [Abstract][Full Text] [Related]
28. Immunohistochemistry of matrix metalloproteinases and their inhibitors in thoracic aortic aneurysms and aortic valves of patients with Marfan's syndrome. Segura AM; Luna RE; Horiba K; Stetler-Stevenson WG; McAllister HA; Willerson JT; Ferrans VJ Circulation; 1998 Nov; 98(19 Suppl):II331-7; discussion II337-8. PubMed ID: 9852923 [TBL] [Abstract][Full Text] [Related]
29. Insight into the profibrinolytic activity of dermatan sulfate: effects on the activation of plasminogen mediated by tissue and urinary plasminogen activators. Castañon MM; Gamba C; Kordich LC Thromb Res; 2007; 120(5):745-52. PubMed ID: 17270255 [TBL] [Abstract][Full Text] [Related]
30. [Expression of urokiase-type plasminogen activator and matrix metalloproteinases in human tissue of abdominal aortic aneurysm]. Li Y; Zhang YW Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct; 25(10):1305-7, 1311. PubMed ID: 16234117 [TBL] [Abstract][Full Text] [Related]
31. In vivo suppression of restenosis in balloon-injured rat carotid artery by adenovirus-mediated gene transfer of the cell surface-directed plasmin inhibitor ATF.BPTI. Lamfers ML; Lardenoye JH; de Vries MR; Aalders MC; Engelse MA; Grimbergen JM; van Hinsbergh VW; Quax PH Gene Ther; 2001 Apr; 8(7):534-41. PubMed ID: 11319620 [TBL] [Abstract][Full Text] [Related]
32. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Heymans S; Luttun A; Nuyens D; Theilmeier G; Creemers E; Moons L; Dyspersin GD; Cleutjens JP; Shipley M; Angellilo A; Levi M; Nübe O; Baker A; Keshet E; Lupu F; Herbert JM; Smits JF; Shapiro SD; Baes M; Borgers M; Collen D; Daemen MJ; Carmeliet P Nat Med; 1999 Oct; 5(10):1135-42. PubMed ID: 10502816 [TBL] [Abstract][Full Text] [Related]
33. Enzymatic modification of low-density lipoprotein in the arterial wall: a new role for plasmin and matrix metalloproteinases in atherogenesis. Torzewski M; Suriyaphol P; Paprotka K; Spath L; Ochsenhirt V; Schmitt A; Han SR; Husmann M; Gerl VB; Bhakdi S; Lackner KJ Arterioscler Thromb Vasc Biol; 2004 Nov; 24(11):2130-6. PubMed ID: 15345515 [TBL] [Abstract][Full Text] [Related]
34. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR. Plesner T; Behrendt N; Ploug M Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652 [TBL] [Abstract][Full Text] [Related]
35. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. Moser TL; Young TN; Rodriguez GC; Pizzo SV; Bast RC; Stack MS Int J Cancer; 1994 Feb; 56(4):552-9. PubMed ID: 8112891 [TBL] [Abstract][Full Text] [Related]
36. Urokinase-mediated extracellular matrix degradation by human prostatic carcinoma cells and its inhibition by retinoic acid. Webber MM; Waghray A Clin Cancer Res; 1995 Jul; 1(7):755-61. PubMed ID: 9816042 [TBL] [Abstract][Full Text] [Related]
37. Proteolytic cleavage of urokinase-type plasminogen activator by stromelysin-1 (MMP-3). Ugwu F; Van Hoef B; Bini A; Collen D; Lijnen HR Biochemistry; 1998 May; 37(20):7231-6. PubMed ID: 9585535 [TBL] [Abstract][Full Text] [Related]
38. Abnormal levels of urokinase plasminogen activator protein and tissue plasminogen activator activity in human aortic aneurysms. Falkenberg M; Holmdahl L; Tjärnström J; Risberg B Eur J Surg; 2001 Jan; 167(1):10-4. PubMed ID: 11213813 [TBL] [Abstract][Full Text] [Related]
39. MMP-12 has a role in abdominal aortic aneurysms in mice. Longo GM; Buda SJ; Fiotta N; Xiong W; Griener T; Shapiro S; Baxter BT Surgery; 2005 Apr; 137(4):457-62. PubMed ID: 15800495 [TBL] [Abstract][Full Text] [Related]